177Lu-FAP-2286

DRUG2 trials

Sponsors

Novartis Pharmaceuticals, Peter MacCallum Cancer Centre, Australia

Conditions

Cancer of Unknown PrimarySolid Tumor

Phase 1

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

RecruitingNCT04939610

Novartis PharmaceuticalsSolid Tumor

Start: 2021-07-30End: 2028-06-30Target: 222Updated: 2026-07-24

Phase 2

Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary

Not yet recruitingNCT07434180

Peter MacCallum Cancer Centre, AustraliaCancer of Unknown Primary

Start: 2026-06-01End: 2030-06-01Target: 20Updated: 2026-02-25

Related Papers

Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial.

2026-06-01

Gallium-68-labeled fibroblast activation protein inhibitor-46 PET in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma: A phase 2, multicenter, single arm, open label non-randomized study protocol

PLoS ONE2023-11-276 citations

Abstract CT251: LuMIERE: A phase 1/2 study investigating safety, pharmacokinetics, dosimetry, and preliminary antitumor activity of 177Lu-FAP-2286 in patients with advanced or metastatic solid tumors

Cancer Research2022-06-1510 citations

Abstract 3317: Comparative biodistribution and radiotherapeutic efficacy of the fibroblast activation protein (FAP)-targeting agents FAP-2286 and FAPI-46

Cancer Research2022-06-154 citations

Abstract LBA032: Pan-cancer analysis of fibroblast activation protein alpha (FAP) expression to guide tumor selection for the peptide-targeted radionuclide therapy FAP-2286

Molecular Cancer Therapeutics2021-12-014 citations